---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000072"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-10-14T13:33:28+00:00"
generated_at: "2026-10-14T13:34:06.875398+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Oncolytics sees final PanCAN grant payment this quarter; GOBLET Cohort 4 data due Q4 2026

## Summary
- Oncolytics (Nasdaq: ONCY) expects the final Pancreatic Cancer Action Network grant payment later this quarter after completing Cohort 5 wind-down activities.
- Final Cohort 4 results, testing pelareorep with atezolizumab in second-line or later squamous cell anal carcinoma, are expected in Q4 2026.
- Initial Cohort 5 results in first-line metastatic pancreatic ductal adenocarcinoma are expected in H1 2027, but could slip as patients stay on treatment.
- CMO Thomas Heineman said Cohort 4 median overall survival exceeds the company's expectations, with the full data set still being processed.
- Oncolytics said every GOBLET cohort that enrolled the required number of patients met its pre-specified efficacy success criteria.

## SEC filing metadata
- accession: 0001129928-26-000072
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-10-14T13:33:28+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000072/0001129928-26-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000072/oncy-20261014.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000072
- JSON: https://secwatch.observer/filing/0001129928-26-000072.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.